With insomnia, the figures are staggering: nearly one-third of Americans experience some level of sleep disruption, and for ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

A new study indicates that the drug suvorexant could reduce proteins associated with Alzheimer's by improving sleep quality.

Suvorexant belongs to a new class of sleep medications called dual orexin receptor antagonists. Orexin is a molecule that promotes wakefulness; suvorexant blocks it, promoting deeper sleep.

People with visual difficulties were significantly more likely to take medication to help them sleep, but that could put them at risk for falls as well, a new study finds. “We found that self ...

Sleep medication usage showed a similar pattern — each additional level of reported use (from “never” to “every night”) was associated with approximately a 20% increase in disability risk.

They found higher levels of both insomnia symptoms and sleep medication use were associated with higher risk of disability a year later. Every year a person experienced an incremental increase in ...

For adults over the age of 65, higher levels of both insomnia symptoms and sleep medication use were associated with higher risk of disability a year later, according to a new study. Insomnia is a ...